rs565893436
Positions:
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM2PP3_StrongPP5
The NM_001360.3(DHCR7):c.862G>A(p.Glu288Lys) variant causes a missense change. The variant allele was found at a frequency of 0.0000285 in 1,613,806 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.000033 ( 0 hom., cov: 34)
Exomes 𝑓: 0.000028 ( 0 hom. )
Consequence
DHCR7
NM_001360.3 missense
NM_001360.3 missense
Scores
11
7
1
Clinical Significance
Conservation
PhyloP100: 6.89
Genes affected
DHCR7 (HGNC:2860): (7-dehydrocholesterol reductase) This gene encodes an enzyme that removes the C(7-8) double bond in the B ring of sterols and catalyzes the conversion of 7-dehydrocholesterol to cholesterol. This gene is ubiquitously expressed and its transmembrane protein localizes to the endoplasmic reticulum membrane and nuclear outer membrane. Mutations in this gene cause Smith-Lemli-Opitz syndrome (SLOS); a syndrome that is metabolically characterized by reduced serum cholesterol levels and elevated serum 7-dehydrocholesterol levels and phenotypically characterized by cognitive disability, facial dysmorphism, syndactyly of second and third toes, and holoprosencephaly in severe cases to minimal physical abnormalities and near-normal intelligence in mild cases. Alternative splicing results in multiple transcript variants that encode the same protein.[provided by RefSeq, Aug 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.972
PP5
Variant 11-71437913-C-T is Pathogenic according to our data. Variant chr11-71437913-C-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 500764.We mark this variant Likely_pathogenic, oryginal submissions are: {Uncertain_significance=3, Likely_pathogenic=4}. Variant chr11-71437913-C-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DHCR7 | NM_001360.3 | c.862G>A | p.Glu288Lys | missense_variant | 8/9 | ENST00000355527.8 | NP_001351.2 | |
DHCR7 | NM_001163817.2 | c.862G>A | p.Glu288Lys | missense_variant | 8/9 | NP_001157289.1 | ||
DHCR7 | XM_011544777.3 | c.862G>A | p.Glu288Lys | missense_variant | 8/9 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DHCR7 | ENST00000355527.8 | c.862G>A | p.Glu288Lys | missense_variant | 8/9 | 1 | NM_001360.3 | ENSP00000347717.4 | ||
DHCR7 | ENST00000685320.1 | c.277G>A | p.Glu93Lys | missense_variant | 7/8 | ENSP00000509319.1 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152192Hom.: 0 Cov.: 34
GnomAD3 genomes
AF:
AC:
5
AN:
152192
Hom.:
Cov.:
34
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 251000Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135662
GnomAD3 exomes
AF:
AC:
4
AN:
251000
Hom.:
AF XY:
AC XY:
2
AN XY:
135662
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000281 AC: 41AN: 1461496Hom.: 0 Cov.: 32 AF XY: 0.0000303 AC XY: 22AN XY: 727054
GnomAD4 exome
AF:
AC:
41
AN:
1461496
Hom.:
Cov.:
32
AF XY:
AC XY:
22
AN XY:
727054
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000328 AC: 5AN: 152310Hom.: 0 Cov.: 34 AF XY: 0.0000269 AC XY: 2AN XY: 74468
GnomAD4 genome
AF:
AC:
5
AN:
152310
Hom.:
Cov.:
34
AF XY:
AC XY:
2
AN XY:
74468
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
2
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:5Uncertain:4
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Smith-Lemli-Opitz syndrome Pathogenic:4Uncertain:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Apr 20, 2018 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 01, 2023 | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 288 of the DHCR7 protein (p.Glu288Lys). This variant is present in population databases (rs565893436, gnomAD 0.006%). This missense change has been observed in individual(s) with Smith–Lemli–Opitz syndrome (PMID: 16392899). ClinVar contains an entry for this variant (Variation ID: 500764). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt DHCR7 protein function with a positive predictive value of 95%. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Oct 10, 2019 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 08, 2023 | Variant summary: DHCR7 c.862G>A (p.Glu288Lys) results in a conservative amino acid change located in the Transmembrane region (Peng_2018) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. A recent study using computational investigation to model the effect on protein and make predictions on SLOS phenotype based on structural and conservation properties reported this variant among Pathogenic alterations in the DHCR7 gene based on lower Relative solvent accesible surface area (rSASA), and higher evolutionary conservation (EC) compared with non-pathogenic variants (example, Peng_2018). This supports the notion of a critical amino acid residue essential for protein function. The variant allele was found at a frequency of 1.6e-05 in 251000 control chromosomes. c.862G>A has been reported in the literature as a compound heterozygous genotype in at-least one individual affected with Smith-Lemli-Opitz Syndrome while an earlier mutational update lists this variant among mutations in patients with Smith-Lemli-Opitz Syndrome without specifying a genotype/zygosity (example, Romano_2005, Witsch-Baumgartner_2001). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 29300326, 16392899, 11241839). Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 (LP, n=2; VUS, n=4). Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Oct 05, 2018 | The DHCR7 c.862G>A (p.Glu288Lys) variant is a missense variant that has been reported in at least two clinical studies in individuals with Smith-Lemli-Opitz syndrome (Witsch-Baumgartner et al. 2001; Romano et al. 2005). Romano et al. (2005) identified the p.Glu288Lys variant in a compound heterozygous state with a second missense variant in one individual with a severe phenotype. Control data are unavailable for the p.Glu288Lys variant, which is reported at a frequency of 0.000016 in the Total population of the Genome Aggregation Database. Functional studies of this variant have not been conducted. The evidence for this variant is limited. The p.Glu288Lys variant is therefore classified as a variant of uncertain significance but suspicious for pathogenicity for Smith-Lemli-Opitz syndrome. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Likely pathogenic, criteria provided, single submitter | curation | Laboratory of Medical Genetics, National & Kapodistrian University of Athens | Feb 01, 2024 | - - |
DHCR7-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 17, 2024 | The DHCR7 c.862G>A variant is predicted to result in the amino acid substitution p.Glu288Lys. This variant has been reported in a cohort of individuals with Smith-Lemli-Opitz syndrome, though no additional information was provided on variant zygosity or patient genotype (Witsch-Baumgartner et al. 2001. PubMed ID: 11241839). It was also reported in the compound heterozygous state with a second DHCR7 variant (p.Ile251Asn) in an individual with Smith-Lemli Opitz syndrome (Romano et al. 2005. PubMed ID: 16392899). This variant is reported in 0.0058% of alleles in individuals of Latino descent in gnomAD. This variant is interpreted as likely pathogenic. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 01, 2020 | The alteration results in an amino acid change:_x000D_ _x000D_ The c.862G>A (p.E288K) alteration is located in exon 8 (coding exon 6) of the DHCR7 gene. This alteration results from a G to A substitution at nucleotide position 862, causing the glutamic acid (E) at amino acid position 288 to be replaced by a lysine (K). The alteration is rare in population databases: _x000D_ _x000D_ Based on data from the Genome Aggregation Database (gnomAD), the c.862G>A alteration was observed in 0.0016% (4/25100) of total alleles studied. The alteration has been observed in affected individuals:_x000D_ _x000D_ This alteration has been described from a cohort of individuals with SLOS, as well as occurring in trans with a second missense variant in one individual with a severe phenotype (Romano, 2005; Witsch-Baumgartner, 2001). The altered amino acid is conserved throughout evolution:_x000D_ _x000D_ The p.E288 amino acid is conserved in available vertebrate species. The amino acid is located in a structurally important protein domain:_x000D_ _x000D_ The p.E288K amino acid is located in the transmembrane domain 6 (TM6) and causes changes in protein dynamics which might lead to protein dysfunction (Peng 2018). The alteration is predicted deleterious by in silico modeling:_x000D_ _x000D_ The p.E288K alteration is predicted to be deleterious by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Mar 07, 2017 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Pathogenic
D;D;D;D;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
.;D;D;D;D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D;D;D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Pathogenic
H;H;.;.;.
PrimateAI
Uncertain
T
PROVEAN
Uncertain
D;D;D;D;D
REVEL
Pathogenic
Sift
Pathogenic
D;D;D;D;D
Sift4G
Pathogenic
D;D;D;D;.
Polyphen
D;D;.;.;.
Vest4
MutPred
Gain of methylation at E288 (P = 0.0115);Gain of methylation at E288 (P = 0.0115);.;.;.;
MVP
MPC
0.61
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at